Thursday, November 14th, 2024

Hyphens Pharma Defies Economic Headwinds: 22% Revenue Surge Despite Q3 Profit Dip








Hyphens Pharma Reports Solid Q3 and 9M Performance Amid Higher Costs

Hyphens Pharma Reports Solid Q3 and 9M Performance Amid Higher Costs

Hyphens Pharma International Limited (SGX: 201735688C) has released its quarterly business update for the third quarter (3Q2024) and the nine months ending September 30, 2024 (9M2024). Despite facing increased operational costs, the company has demonstrated robust revenue growth, driven by strong sales in its core markets and segments.

Key Financial Highlights

  • 3Q2024 Revenue: S\$43.9 million (up 2.5% from 3Q2023)
  • 9M2024 Revenue: S\$143.5 million (up 22.1% from 9M2023)
  • 3Q2024 Gross Profit: S\$17.0 million (up 12.1% from 3Q2023)
  • 9M2024 Gross Profit: S\$51.8 million (up 19.9% from 9M2023)
  • 3Q2024 Net Profit After Tax: S\$2.0 million (down 5.6% from 3Q2023)
  • 9M2024 Net Profit After Tax: S\$7.5 million (up 32.6% from 9M2023)

Revenue Drivers

Several factors contributed to the revenue growth:

  1. Specialty Pharma Principals Segment: Revenue increased by 32.6%, driven by new distributorships with Laboratoires Gilbert S.A.S and heightened sales from the medical aesthetics range.
  2. Proprietary Brands Segment: Revenue improved by 16.9%, bolstered by higher sales of Ceradan® dermatological products and Ocean Health® health supplements.
  3. Medical Hypermart and Digital Segment: Revenue rose by 3.0%.

Operational Costs and Profit Margins

Despite the revenue growth, the company faced higher distribution costs, increased manpower expenses, and rising administrative costs. The gross profit margin for 3Q2024 was 38.7%, an improvement from 35.4% in 3Q2023. However, the gross profit margin for 9M2024 slightly declined to 36.1% from 36.7% in 9M2023.

Foreign Exchange Gains

The company benefited from favorable local currency exchange rate movements against the USD and EURO, which are the major currencies for supplies.

Implications for Shareholders

Shareholders should note the significant revenue growth, which may positively influence the company’s share value. However, the increase in operational costs and the slight decline in the gross profit margin over nine months could be a concern. The company’s ability to manage these costs while sustaining revenue growth will be crucial for future performance.

BY ORDER OF THE BOARD
Flora Zhang
Chief Financial Officer
12 November 2024

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own research or consult a financial advisor before making any investment decisions.




View Hyphens Pharma Historical chart here



Goldwind Science & Technology (2208 HK): Record Order Backlog and Strong Earnings Propel Growth

Date of Report: October 29, 2024Broker: UOB Kay Hian Private Limited Company Overview Goldwind Science & Technology (2208 HK) is the largest wind turbine generator (WTG) manufacturer in China, holding over 30% of the...

Resilient Performance Amid Overseas Challenges: Mapletree Pan Asia Commercial Trust’s Strategic Outlook

Date of Report: October 25, 2024Broker: CGS International 1. Overview of 1HFY3/25 Performance Mapletree Pan Asia Commercial Trust (MPACT) reported a 1HFY3/25 Distribution Per Unit (DPU) of 4.07 Singapore cents, which marked a 7.9%...

Sino Biopharmaceutical Ltd Positioned for Strong Gains with Technical Buy Momentum

Date: September 17, 2024Broker: CGS-CIMB Securities Company Overview Sino Biopharmaceutical Ltd (Stock Code: 1177) is a major pharmaceutical company based in Hong Kong. It focuses on the research, development, production, and distribution of biopharmaceutical...